MEDINCELL S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.66 EUR | +2.10% |
|
+14.05% | +75.83% |
| Apr. 17 | Medincell: share price rises following agreement with AbbVie | CF |
| Apr. 16 | Medincell, AbbVie to Co-Develop Injectable Therapeutics | DJ |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 125.5 | 119.8 | 287.6 | 186.4 | 246.2 | 364 | - | - |
| Enterprise Value (EV) 1 | 157.3 | 119.8 | 287.6 | 209.3 | 294.4 | 412.7 | 422.8 | 405.6 |
| P/E ratio | -5.48 x | -5.01 x | -13.6 x | -7.42 x | -7.72 x | -13.9 x | -237 x | 21.5 x |
| Yield | - | - | - | - | - | - | - | 3.79% |
| Capitalization / Revenue | 87 x | 42 x | 35.1 x | 45.6 x | 24.9 x | 26.1 x | 8.69 x | 7.1 x |
| EV / Revenue | 109 x | 42 x | 35.1 x | 51.2 x | 29.8 x | 29.6 x | 10.1 x | 7.91 x |
| EV / EBITDA | - | - | - | -9.39 x | -13.2 x | -21.9 x | 61 x | 15.7 x |
| EV / FCF | -9.46 x | - | - | -9.1 x | -13.4 x | -15.7 x | -67.1 x | 34.5 x |
| FCF Yield | -10.6% | - | - | -11% | -7.48% | -6.38% | -1.49% | 2.9% |
| Price to Book | - | - | - | -13.9 x | -5.86 x | -7.54 x | -5.92 x | -9.81 x |
| Nbr of stocks (in thousands) | 20,086 | 20,097 | 24,581 | 25,121 | 25,101 | 28,749 | - | - |
| Reference price 2 | 6.250 | 5.960 | 11.70 | 7.420 | 9.810 | 12.66 | 12.66 | 12.66 |
| Announcement Date | 6/4/19 | 6/4/20 | 6/16/21 | 6/14/22 | 6/26/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.443 | 2.852 | 8.186 | 4.091 | 9.889 | 13.96 | 41.88 | 51.29 |
| EBITDA 1 | - | - | - | -22.3 | -22.36 | -18.81 | 6.927 | 25.81 |
| EBIT 1 | -15.52 | -19.32 | -15.37 | -23.81 | -24.02 | -19.93 | 2.04 | 20.73 |
| Operating Margin | -1,075.26% | -677.56% | -187.74% | -582.06% | -242.95% | -142.8% | 4.87% | 40.41% |
| Earnings before Tax (EBT) 1 | -19.71 | - | - | -24.81 | -32.01 | -21.26 | 3.69 | 28.17 |
| Net income 1 | -19.69 | -23.92 | -19.02 | -24.81 | -29.5 | -23.63 | 1.406 | 15.59 |
| Net margin | -1,364.31% | -838.53% | -232.35% | -606.36% | -298.29% | -169.27% | 3.36% | 30.4% |
| EPS 2 | -1.140 | -1.190 | -0.8600 | -1.000 | -1.270 | -0.9133 | -0.0533 | 0.5900 |
| Free Cash Flow 1 | -16.63 | - | - | -22.98 | -22.03 | -26.32 | -6.3 | 11.75 |
| FCF margin | -1,152.6% | - | - | -561.84% | -222.79% | -188.58% | -15.04% | 22.91% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 45.52% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 75.36% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 0.4800 |
| Announcement Date | 6/4/19 | 6/4/20 | 6/16/21 | 6/14/22 | 6/26/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|
| Net sales 1 | 3.862 | 6.985 | 5.212 |
| EBITDA 1 | - | - | -8.934 |
| EBIT 1 | -12.37 | - | -9.811 |
| Operating Margin | -320.38% | - | -188.24% |
| Earnings before Tax (EBT) 1 | - | - | -14.19 |
| Net income 1 | -15.75 | -8.158 | -9.282 |
| Net margin | -407.85% | -116.79% | -178.09% |
| EPS 2 | - | - | -0.3200 |
| Dividend per Share | - | - | - |
| Announcement Date | 6/26/23 | 12/19/23 | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 31.7 | - | - | 22.9 | 48.2 | 48.7 | 58.8 | 41.6 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -1.026 x | -2.155 x | -2.591 x | 8.493 x | 1.612 x |
| Free Cash Flow 1 | -16.6 | - | - | -23 | -22 | -26.3 | -6.3 | 11.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | -0.5300 | -1.670 | -1.680 | -2.140 | -1.290 |
| Cash Flow per Share 2 | - | - | - | - | -0.8300 | -1.000 | -0.7000 | -0.1000 |
| Capex 1 | 0.7 | - | - | 1.97 | 1.03 | 0.8 | 1.48 | 1.6 |
| Capex / Sales | 48.51% | - | - | 48.25% | 10.39% | 5.73% | 3.52% | 3.12% |
| Announcement Date | 6/4/19 | 6/4/20 | 6/16/21 | 6/14/22 | 6/26/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.66
EUR
Average target price
17.15
EUR
Spread / Average Target
+35.47%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +75.83% | 389M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- MEDCL Stock
- Financials MedinCell S.A.
